Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy

BACKGROUND: Lipegfilgrastim is a novel glyco-pegylated granulocyte-colony stimulating factor in development for neutropenia prophylaxis in cancer patients receiving chemotherapy. This phase III, double-blind, randomized, active-controlled, noninferiority trial compared the efficacy and safety of lip...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Bondarenko, Igor, Gladkov, Oleg A, Elsaesser, Reiner, Buchner, Anton, Bias, Peter
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2013
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3751756/
https://ncbi.nlm.nih.gov/pubmed/23945072
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-13-386
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi